BCWORLD PHARM Balance Sheet Health
Financial Health criteria checks 1/6
BCWORLD PHARM has a total shareholder equity of ₩77.7B and total debt of ₩89.6B, which brings its debt-to-equity ratio to 115.3%. Its total assets and total liabilities are ₩180.3B and ₩102.6B respectively. BCWORLD PHARM's EBIT is ₩4.3B making its interest coverage ratio 0.9. It has cash and short-term investments of ₩8.3B.
Key information
115.3%
Debt to equity ratio
₩89.61b
Debt
Interest coverage ratio | 0.9x |
Cash | ₩8.31b |
Equity | ₩77.71b |
Total liabilities | ₩102.63b |
Total assets | ₩180.33b |
Recent financial health updates
BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of Debt
Mar 01Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?
Nov 18Recent updates
Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) Earnings
Mar 18BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of Debt
Mar 01Does The Market Have A Low Tolerance For BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Mixed Fundamentals?
Feb 09Is BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) A Good Dividend Stock?
Jan 25If You Had Bought BCWorld Pharm (KOSDAQ:200780) Stock A Year Ago, You Could Pocket A 75% Gain Today
Jan 11Do Insiders Own Lots Of Shares In BCWorld Pharm Co., Ltd. (KOSDAQ:200780)?
Dec 26Are BCWorld Pharm's (KOSDAQ:200780) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?
Nov 18Financial Position Analysis
Short Term Liabilities: A200780's short term assets (₩45.2B) do not cover its short term liabilities (₩91.2B).
Long Term Liabilities: A200780's short term assets (₩45.2B) exceed its long term liabilities (₩11.4B).
Debt to Equity History and Analysis
Debt Level: A200780's net debt to equity ratio (104.6%) is considered high.
Reducing Debt: A200780's debt to equity ratio has increased from 59.2% to 115.3% over the past 5 years.
Debt Coverage: A200780's debt is not well covered by operating cash flow (10.4%).
Interest Coverage: A200780's interest payments on its debt are not well covered by EBIT (0.9x coverage).